Seminars in Radiation Oncology
Volume 20, Issue 3 , Pages 186-191 , July 2010

Combined Modality Therapy for Stage III Non–Small-Cell Lung Cancer

  • Cynthia S. Anderson, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Cynthia S. Anderson, MD, Department of Radiation Oncology, Emory University School of Medicine, Emory Winship Cancer Institute, Atlanta, GA 30322
    • ,
  • Walter J. Curran, MD

References 

  1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8–29
  2. Vallières E, Shepherd FA, Crowley J, et al. The IASLC lung cancer staging project: Proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol. 2009;4:1049–1059
  3. AJCC. Cancer Staging Manual. (ed 6). New York, NY: Springer-Verlag; 2002;
  4. Depierre A, Milleron B, Moro-Sibilot D, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non–small-cell lung cancer. J Clin Oncol. 2002;20:247–253
  5. Perez CA, Stanley K, Rubin P, et al. A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung (Preliminary report by the Radiation Therapy Oncology Group). Cancer. 1980;45:2744–2753
  6. Roth JA, Fosella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIa non-small cell lung cancer. J Natl Cancer Inst. 1994;86:673–680
  7. Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing perioperative chemotherapy plus surery with surgery alone in patients with non-small cell lung cancer. N Engl J Med. 1994;330:153–158
  8. Depierre A, Milleron B, Moro-Sibilot D, et al. Perioperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0) (II, And IIIa non-small cell lung cancer). J Clin Oncol. 2002;20:247–253
  9. Pisters K, Vallieres E, Bunn P, et al. S9900: A phase III trial of surgery alone or surgery plus preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Preliminary results. Proc Am Soc Clin Oncol. 2005;23:16S
  10. Albain KS, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: Mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol. 1995;13:1880–1892
  11. Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: A phase III randomised controlled trial. Lancet. 2009;1:379–386
  12. Van Meerbeeck JP, Kramer GWP, Van Schil PEY, et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIa non-small cell lung cancer. J Natl Cancer Inst. 2007;99:442–450
  13. Curran WJ, Scott CB, Langer CJ, et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresectable stage III NSCLC. Proc Am Soc Clin Oncol. 2003;22:621
  14. Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small cell lung cancer. N Engl J Med. 1990;323:940–945
  15. Albain KS, Crowley JJ, Turrisi AT, et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: A Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol. 2002;16:3454–3460
  16. Schaake-Koning C, van den Bogaert W, Delasio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med. 1992;326:524–530
  17. Sause W, Kolesar P, Taylor S, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest. 2000;117:358–364
  18. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized trials. BMJ. 1995;311:899–909
  19. Auperin A, Le Pechoux C, Pignon JP, et al. on behalf of the Meta-Analysis of Cisplatin/Carboplatin Based Concomitant Chemotherapy in Non-Small Cell Lung Cancer (MAC3-LC) Group Concomitant radio-chemotherapy based on plating compounds in patients with locally advanced non-small cell lung cancer (NSCLC) (A meta-analysis of individual data from 1764 patients). Ann Oncol. 2006;17:473–483
  20. Le CT, Arriagada R, Tarayre M, et al. Significant effect of adjuvant chemotherapy on survival in locally advanced non-small-cell lung carcinoma. J Natl Cancer Inst. 1992;84:58
  21. Furuse K, Fukuoka M, Nishiyaki Y, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol. 1999;17:2692–2699
  22. Pierre F, Maurice P, Gilles R, et al. A randomized phase III Trial of sequential chemoradiotherapy versus concurrent chemoradiotherapy in locally advanced non-small cell lung cancer (NSCLC) (GLOT-GFPC NPC95-01) Pro. Am Soc Clin Oncol. 2001;20:312A
  23. Vokes E, Herndon J, Turrisi A. Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer (NSCLC): Initial analysis of a randomized phase III trial. Proc Am Soc Clin Oncol. 2004;23:616A
  24. Belani CP, Choy H, Bonomi P, et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small cell lung cancer: A randomized phase II locally advanced multi-modality protocol. J Clin Oncol. 2005;23:5883–5891
  25. Belderbos J, Uitterhoeve L, van Zandwijk N, et al. Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer. Eur J Cancer. 2007;43:114–121
  26. Pu AT, Harrison AS, Robertson JM, et al. The toxicity of elective nodal irradiation in the definitive treatment of non-small cell carcinoma of the lng. Int J Radiat Oncol Biol Phys. 1997;39:196
  27. Senan S, De Ruysscher D, Giraud P, et al. Literature-based recommendations for treatment planning and exection for high-precision radiotherapy in lung cancer. Radiother Oncol. 1997;71:139–146
  28. Yuan S, Sun X, Li M, et al. A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer. Am J Clin Oncol. 2007;30:239–244
  29. Socinski MA, Schell MJ, Peterman A, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol. 2002;20:1335–1343
  30. Rosenman JG, Halle JS, Socinski MA, et al. High-dose conformal radiotherapy for treatment of stage IIIA/B non-small cell lung cancer: Technical issues and results for a phase I/II trial. Int J Radiat Oncol Biol Phys. 2002;54:348–356
  31. Bradley J, Graham MV, Winter K, et al. Phase I results of RTOG 0117: A phase I/II dose intensification study using 3D-CRT and concurrent chemotherapy for patients with inoperable non-small cell lung cancer. J Clin Oncol. 2005;23:16S 7063
  32. Schild S, McGinnis WL, Graham D, et al. Results of a phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2006;65:1106–1111
  33. Socinski M, Rosenman J, Halle J, et al. Dose escalating conformal thoracic radiation therapy with induction concurrent carboplatin/paclitaxel in unresectable stage IIIa and IIIb non-small cell lung cancer: A modified phase I/II trial. Cancer. 2001;92:1213–1223
  34. Bradley J, Schild S, Bogart J, et al. RTOG 0617/ NCCTG N0628/ CALGB 30609/ ECOG R0617: A randomized phase III comparison of standard-dose (60 Gy) versus High-Dose (74 Gy) conformal radiotherapy with concurrent and consolidation carboplatin/paclitaxel +/− cetuximab (IND #103444) in patients with stage IIIa/IIIb non-small cell lung cancer. http://www.rtog.orgAccessed October 30, 2009
  35. Kelly K, Chansky K, Gaspar L, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small cell lung cancer: SWOG S0023. J Clin Oncol. 2008;26:2450–2456
  36. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small cell lung cancer. J Clin Oncol. 2004;22:2184–2191
  37. Sandler A, Gray R, Perry MC, et al. Paclitaxel–carboplatin alone or with bevacizumab for non–small-cell lung cancer. N Engl J Med. 2006;355:2542–2550
  38. Perez-Soler R, Chachoua A, Hammond L, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol. 2004;22:3238–3247
  39. Riely GJ, Rizvi NA, Kris MG, et al. Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non–small-cell lung cancer. J Clin Oncol. 2009;27:264–270
  40. Lynch TJ. A randomized multicenter phase III study of cetuximab (Erbitux) in combination with taxane/ carboplatin versus taxane/carboplatin alone as first-line treatment for patients with advanced/metastatic non-small cell lung cancer (NSCLC): B3-03. J Thorac Oncol. 2007;2:S340–S341
  41. Blumenschein GR, Paulus R, Curran WJ, et al. A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (PTS) with stage IIIA/B non-small cell lung cancer (NSCLC): A report of the 2 year and median survival (MS) for the RTOG 0324 trial. Proc Am Soc Clin Oncol. 2008;26:15S;(abst)

PII: S1053-4296(10)00015-9

doi: 10.1016/j.semradonc.2010.01.007

Seminars in Radiation Oncology
Volume 20, Issue 3 , Pages 186-191 , July 2010

Article Tools